Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAG-RED: Magnesium Supplementation to Reduce Cisplatin-Induced AKI
jRCT1041240185Not yet recruiting
- Sponsor
- N/A
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of magnesium in acute kidney failure (AKF) (2 arms), sponsored by N/A. Primary endpoint: Change in eGFR with vs without magnesium supplementation. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
magnesium
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on jRCT1041240185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240185.